Slides From Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic Goals in Type 2 Diabetes

Learn about the appropriate use of GLP-1 RAs to address elevated A1C, obesity, and CV risk, as well as strategies to improve tolerability and adherence.
John J. Russell, MD
Neil Skolnik, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.40 MB
Released: December 23, 2019

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.

Related Content

Concise microlearning module featuring expert insight on the cardiorenal benefits of finerenone in T2D and CKD from Clinical Care Options (CCO)

Vivian A. Fonseca, MD, FRCP
Program Director
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: August 4, 2022 Expired: August 3, 2023

Commentary on clinical use of SGLT2 inhibitors in diabetic kidney disease, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 21, 2022

Concise microlearning module featuring expert insight on the cardiorenal benefits of SGLT2 inhibitors in T2D from Clinical Care Options (CCO)

Jennifer B. Green, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: July 12, 2022 Expired: July 11, 2023

Unlocked downloadable slides featuring an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings